Store

Kratom has been associated with cases of acute liver injury, including a small number of severe cases.
That does not mean everyone who uses kratom will develop liver problems. It also does not mean researchers know exactly how much kratom causes liver injury or which people are most susceptible.
The current evidence supports a more careful conclusion:
Kratom-associated liver injury appears uncommon, but documented cases show that it can be serious. Researchers have not established a reliable dose threshold, a predictable at-risk population, or a precise incidence rate.
A 2026 systematic review of kratom-associated liver injury identified 32 published cases across 31 studies. Most cases improved after kratom was stopped, but four progressed to liver transplantation. The review also found that information about kratom amount, formulation, frequency, and duration was frequently incomplete, making it difficult to determine why certain people developed liver injury.
That means neither of these statements accurately reflects the science:
“Kratom destroys your liver.”
or:
“Kratom is harmless to the liver if you are otherwise healthy.”
The reality lies between those extremes.
Kratom is the common name for Mitragyna speciosa, a tropical tree native to Southeast Asia and part of the same botanical family as coffee.
Its leaves contain numerous alkaloids.
The best known include:
Mitragynine is generally the most abundant major alkaloid in traditional kratom leaf and has been studied extensively in kratom pharmacology.
Kratom products can differ substantially in composition, however. Traditional leaf, powders, teas, extracts, enhanced products, and concentrated kratom-related formulations should not automatically be assumed to have identical alkaloid profiles.
That product variability is important when interpreting safety research.
The liver performs hundreds of biological functions.
Among other things, it:
It is common to describe the liver as a “filter,” but that is incomplete.
The liver does not simply trap toxins. It uses enzymes and other biochemical pathways to transform many substances into different compounds.
That distinction matters when discussing kratom.
The fact that kratom alkaloids are metabolized by the liver does not, by itself, prove that they “strain” or damage the liver.
Published evidence supports an association between kratom and clinically apparent acute liver injury.
The National Institutes of Health's LiverTox review of kratom classifies kratom as a likely cause of clinically apparent liver injury and describes reported cases involving jaundice and cholestatic or mixed patterns of injury.
The U.S. National Center for Complementary and Integrative Health also includes liver problems among the rare but serious adverse effects reported with kratom.
The key word is reported.
Published cases establish that liver injury can occur.
They do not tell us precisely how frequently it occurs among everyone who uses kratom.
The most current major evidence review was published in March 2026 in the Journal of Addiction Medicine.
The systematic review examined all identified studies of kratom use and liver toxicity and included:
Only 3 of the 32 patients had documented baseline liver disease.
Just 7 of the 32 cases provided complete information about kratom dose, product form, frequency, and duration.
That last finding is especially important.
It means the available case literature cannot establish a dependable relationship such as:
“This amount is safe for the liver.”
or:
“Liver damage only occurs above this amount.”
We do not currently know the precise incidence.
That is an important limitation.
A collection of 32 published cases does not tell us the percentage of all kratom consumers who develop liver injury because we do not know the appropriate denominator.
Case reports are also subject to publication bias. Unusual and severe events are much more likely to be written up in medical journals than uneventful use.
NCCIH describes serious liver problems as rare among reported kratom effects, but the exact population-level risk has not been established.
The scientifically defensible conclusion is:
Kratom-associated liver injury appears uncommon based on available evidence, but its true incidence remains uncertain.
One of the strongest individual datasets comes from the U.S. Drug-Induced Liver Injury Network, or DILIN.
Researchers identified 11 cases judged definite, highly likely, or probable for kratom-associated liver injury between 2003 and 2019.
In the published DILIN case series:
The median peak bilirubin concentration was substantially elevated, illustrating the degree of jaundice present in many of these cases.
This series provides strong evidence that kratom can be associated with clinically significant liver injury.
It does not establish how likely that outcome is for the average person using kratom.
The DILIN series contained no deaths or liver transplants.
The broader 2026 systematic review identified four published cases that progressed to liver transplantation.
These findings are not contradictory.
The DILIN study examined one defined U.S. research cohort.
The newer systematic review searched a broader published literature.
Together, they show that:
Most reported patients improved, but severe outcomes have occurred.
That is more accurate than saying kratom-associated liver injury always resolves after the product is discontinued.
Published cases frequently describe symptoms developing during the first several weeks of exposure, but there is no single timeline.
A comprehensive review of reported kratom liver injury found a median latency of approximately 20.6 days, with reported symptom onset ranging from 2 to 49 days.
The DILIN series found a median of 14 days, with a 5-to-28-day range.
The NIH LiverTox review describes typical onset as occurring within approximately 1 to 8 weeks after regular use begins.
These ranges should not be interpreted as a countdown.
Cases outside a typical range can occur, and current evidence does not show that reaching a particular number of days without symptoms eliminates future risk.
Drug-induced liver injury can take several biochemical forms.
Cholestatic injury involves problems related to bile formation or flow.
It may be associated with:
The 2026 systematic review found that the reported kratom cases were predominantly cholestatic.
Hepatocellular injury primarily involves damage to liver cells and may produce larger increases in enzymes such as ALT and AST.
Some cases show characteristics of both hepatocellular and cholestatic injury.
In the DILIN series, 6 of the 11 patients had a mixed pattern, with smaller numbers classified as cholestatic or hepatocellular.
The variation between studies reinforces that kratom-associated liver injury does not always present identically.
Symptoms described across published kratom-associated liver-injury cases include:
The NIH LiverTox summary describes fatigue, nausea, itching, dark urine, and subsequent jaundice among characteristic presentations.
These symptoms are not specific to kratom.
Many liver, gallbladder, infectious, metabolic, and medication-related conditions can produce similar signs.
Jaundice or dark urine accompanied by significant illness warrants prompt medical evaluation rather than assuming kratom is or is not the cause.
Clinicians do not diagnose kratom-associated liver injury from symptoms alone.
Evaluation commonly includes laboratory measurements such as:
Doctors may also evaluate for competing explanations, including viral hepatitis, autoimmune conditions, bile-duct obstruction, alcohol-related injury, medications, supplements, and other exposures.
That is important because drug-induced liver injury is largely a diagnosis of exclusion.
The DILIN cases underwent detailed evaluation before expert reviewers classified kratom as definite, highly likely, or probable as the cause.
Most published cases have improved, but severe liver dysfunction has been reported.
The 2026 systematic review found that four published cases progressed to liver transplantation.
That does not mean liver transplantation occurs in a meaningful percentage of all kratom users.
The systematic review collected published liver-injury cases, not a representative sample of kratom consumers.
It demonstrates severity is possible, not how frequently it occurs.
Current research does not establish that.
This is one of the biggest misconceptions to avoid.
The 2026 systematic review found that information about amount, frequency, formulation, and duration was missing or incomplete in most cases. Only 7 of 32 contained complete exposure information.
Without consistent exposure data, researchers cannot calculate a reliable dose-response relationship.
That means we do not currently have evidence for a rule such as:
“Small amounts cannot affect the liver.”
or:
“Liver injury begins above X grams.”
No validated liver-safe gram threshold has been established.
Current human evidence has not established a specific amount guaranteed to avoid liver injury.
This is especially important because drug-induced liver injury is not always a straightforward overdose phenomenon.
Some forms of drug-induced liver injury are idiosyncratic, meaning they occur unpredictably in susceptible individuals rather than appearing uniformly once a specific amount is crossed.
Researchers have not yet established whether kratom-associated liver injury follows one mechanism in every case.
For that reason, a liver-safety article should not provide a “safe dosage range.”
No.
Preexisting liver disease is not required for reported kratom-associated liver injury.
In the 2026 systematic review, only 3 of 32 patients had documented baseline liver disease.
Likewise, the DILIN researchers described the typical patient in their series as otherwise relatively healthy before presenting with jaundice and liver injury.
This does not mean people with liver disease face the same risks as everyone else.
It means researchers cannot currently say:
“A healthy liver protects you from kratom-associated liver injury.”
Current evidence does not provide a validated risk calculator.
Researchers do not yet know how to reliably predict susceptibility according to:
The DILIN investigators observed several genetic characteristics that may warrant additional study, but the sample was far too small to create a clinically useful genetic risk profile.
The 2020 comprehensive review similarly concluded that it remains unclear which subgroups of kratom consumers face heightened liver risk.
No.
“Kratom” now describes products with substantially different compositions.
Products may include:
The 2026 liver-injury review found product-form information was often incomplete, which limits our ability to compare liver risk among these formulations.
This means evidence from ordinary leaf should not automatically be used to declare that every concentrated product has the same risk profile.
The opposite is also true.
Evidence about a concentrated formulation should not automatically be applied to every traditional leaf product.
7-hydroxymitragynine occurs naturally in kratom leaf at relatively low concentrations.
Some newer commercial products contain added or enhanced amounts of 7-OH and therefore differ substantially from traditional botanical leaf.
The FDA specifically distinguishes concentrated or enhanced 7-OH products from naturally occurring kratom leaf, noting that 7-OH occurs naturally only in trace amounts in the plant.
That distinction matters when reading kratom research.
A study of ordinary kratom leaf cannot automatically tell us the safety profile of a chemically different concentrated 7-OH product.
However, current liver-injury evidence is not sufficient to quantify how liver risk differs among those product categories.
Product contamination is a legitimate issue, but available evidence does not support blaming every liver-injury case on contaminants.
NCCIH notes that some kratom products have been found to contain harmful contaminants, including heavy metals and disease-causing bacteria.
However, DILIN researchers chemically analyzed three available products implicated in their liver-injury cases.
Those samples contained mitragynine and 7-hydroxymitragynine, and investigators did not identify the other pharmaceutical adulterants, toxicants, or contaminants they tested for.
Three products are far too few to establish what is present in the entire kratom market.
But the result demonstrates why this explanation is too simple:
“Kratom doesn't affect the liver. Contaminants are the real problem.”
Contamination may complicate some cases, but it does not currently explain away the kratom-associated liver-injury evidence.
Not yet.
The NIH LiverTox review states that the mechanism of kratom-associated liver injury remains unknown.
Several possibilities are scientifically interesting, including:
But none currently provides a complete established mechanism.
Saying the liver is simply “overworked” by having to process many kratom alkaloids is therefore not an evidence-based explanation.
Mitragynine is extensively metabolized.
Research using human liver preparations found that the cytochrome P450 enzyme CYP3A4 plays a major role in mitragynine metabolism, with smaller contributions from CYP2D6 and CYP2C9.
That finding has now been strengthened by human research.
A 2024 clinical pharmacokinetic study examined kratom tea with and without itraconazole, a strong CYP3A4 inhibitor.
When CYP3A4 activity was inhibited:
The researchers concluded that the study provided direct evidence of CYP3A4-mediated formation of 7-hydroxymitragynine in humans.
Not by itself.
This distinction is important.
CYP3A4 involvement tells us something about how mitragynine is metabolized.
It does not prove that CYP3A4 metabolism is the mechanism causing liver injury.
Many substances are metabolized by CYP enzymes without producing clinically significant liver injury.
Researchers continue to investigate kratom's potential for drug interactions and metabolism-related effects, but those questions should not be collapsed into:
“CYP3A4 metabolizes kratom, therefore CYP3A4 causes kratom liver damage.”
The mechanism of kratom-associated liver injury remains unresolved.
Interaction potential is an active research area.
The human CYP3A4 study demonstrates that altering a drug-metabolizing enzyme can substantially change mitragynine and 7-OH exposure.
A separate 2026 case report described both liver-enzyme abnormalities and altered concentrations of a CYP-metabolized medication during long-term kratom exposure, with both improving after kratom cessation. As a single case report, it cannot establish how frequently such an interaction occurs.
The broader point is that drug-interaction potential and direct liver toxicity are related research questions but not the same phenomenon.
The current case literature does not allow us to calculate a specific combined liver risk for kratom and alcohol.
Some published cases involved alcohol or other substances, while others did not.
In the DILIN series, several participants reported alcohol use, but the investigators still classified the cases as definite, highly likely, or probable kratom-associated liver injury after evaluating alternative causes.
The evidence therefore does not support either extreme:
“Alcohol explains all kratom liver cases.”
or:
“Alcohol has no relevance.”
Concurrent exposures are one of several factors researchers need to understand better.
Drug-induced liver injury, usually abbreviated DILI, is liver damage attributed to a medication, supplement, botanical, or other chemical exposure.
Despite the word “drug,” DILI can involve:
A substance does not need to be a prescription medication to produce this type of injury.
When a botanical product is involved, the condition may also be described as herb-induced liver injury.
Determining causality can be challenging because doctors must consider other possible causes.
Published cases commonly describe relatively acute presentations, often within weeks of beginning exposure.
That does not establish that every possible liver effect follows the same timeline.
Current evidence is built heavily from case reports of clinically obvious injury.
Those reports are better at identifying events such as:
than determining whether lower-level or long-term changes occur in the broader population.
This is another area where more research is needed.
Not in every case.
Many reported patients have recovered.
In the DILIN series, all 11 eventually recovered, although normalization sometimes took months.
The 2026 systematic review likewise found improvement in most reported cases after kratom use stopped.
However, four cases in the broader review progressed to liver transplantation.
So the evidence does not support saying that kratom liver injury is always temporary or always permanent.
Outcomes have varied.
Jaundice is yellow discoloration of the skin or whites of the eyes caused by elevated bilirubin in the blood.
Bilirubin is produced during the normal breakdown of red blood cells and is processed through the liver and biliary system.
Because cholestatic injury interferes with normal bile processing or flow, bilirubin can accumulate.
That is why jaundice and dark urine appear so frequently in published kratom-associated liver-injury reports.
These laboratory measurements help clinicians characterize liver injury.
Alanine aminotransferase is an enzyme found primarily in liver cells. Higher levels can indicate liver-cell injury.
Aspartate aminotransferase is found in the liver and other tissues. It is interpreted alongside other laboratory findings.
Alkaline phosphatase can increase in cholestatic or bile-related liver injury, although it can also come from other tissues.
Elevated bilirubin can produce jaundice and dark urine.
Doctors examine these measurements together rather than diagnosing liver injury from one value alone.
Not reliably.
Some liver injury produces obvious symptoms, but abnormal liver tests can also occur without dramatic symptoms.
At the same time, symptoms such as fatigue, nausea, or abdominal discomfort have many possible causes and do not establish liver damage on their own.
This is why suspected drug- or supplement-associated liver injury is evaluated medically rather than diagnosed from an online symptom list.
Jaundice, dark urine, persistent severe itching, significant abdominal pain, or other signs suggesting liver dysfunction should not be self-diagnosed or managed solely through online advice.
Prompt medical evaluation is appropriate when symptoms suggest possible liver injury, particularly jaundice.
Doctors can evaluate liver chemistry and investigate alternative causes that may require treatment.
Most published cases improved after kratom exposure ended, but that should not be interpreted as a guarantee that simply stopping at home will resolve every case.
The 2026 systematic review found improvement in most cases but also identified four patients who required liver transplantation.
The NIH LiverTox review similarly notes that recovery is common but that cholestatic illness can sometimes be prolonged.
Someone with suspected liver injury needs medical evaluation rather than relying on a prediction based on published averages.
The literature does not identify a kratom-specific antidote.
The NIH LiverTox review notes that treatments such as corticosteroids and N-acetylcysteine have been used in individual suspected cases, but evidence that they specifically improve kratom-associated liver injury is not established.
Clinical management depends on the severity and pattern of the injury and on excluding other causes.
For a consumer article, the key point is that treatment decisions belong in medical care, not in a kratom dosing guide.
There is no useful evidence-based way to rank these substances with a simple statement such as:
“Kratom is easier on the liver.”
Different substances produce liver injury through different mechanisms and at different population frequencies.
Acetaminophen, alcohol, kratom, medications, and herbal products therefore should not be placed on a simplistic universal “liver toxicity” scale.
The fact that one substance has known liver risks does not establish another as harmless.
No.
Kratom and coffee belong to the same botanical family, Rubiaceae.
Botanical relationship does not mean two plants contain the same chemicals or have the same safety profile.
Kratom contains a distinct alkaloid mixture with pharmacology very different from caffeine.
The coffee comparison is useful for plant taxonomy, not for predicting liver safety.
Current human evidence does not provide a reliable comparative liver-risk estimate.
Concentrated extracts may expose consumers to different amounts and ratios of alkaloids than traditional leaf.
But the 2026 systematic review found that product form and exposure details were often inadequately reported.
It would therefore go beyond the evidence to claim:
“Extracts cause more liver damage.”
or:
“Leaf powder cannot affect the liver.”
Better comparative research is needed.
Laboratory testing can provide useful information about product composition and specified contaminants.
Depending on the analytical panel, testing may examine:
But a laboratory report cannot guarantee that an individual will not experience an idiosyncratic adverse reaction.
It also only tells you about the tests actually performed.
A COA should therefore be viewed as product information, not proof that liver injury is impossible.
Yes.
NCCIH reports that harmful contaminants, including heavy metals and disease-causing bacteria, have been found in some kratom products.
That makes manufacturing and testing relevant consumer information.
But contamination and kratom-associated liver injury should not be treated as identical issues.
Published DILIN cases included analyzed products in which the investigators found expected kratom alkaloids without the other adulterants or toxicants they tested for.
Despite the expanding literature, several basic questions remain unresolved.
Researchers still need better evidence about:
The 2026 systematic review specifically emphasizes incomplete exposure reporting and the need for substantially better research into the mechanisms of kratom-associated liver injury.
Kratom has been associated with clinically significant liver injury in published cases.
That does not establish that liver injury occurs in everyone who uses kratom.
The exact population-level risk remains uncertain.
There is no validated scale that allows researchers to say kratom puts a certain amount of “strain” on the liver.
The better-established finding is that kratom has been associated with uncommon but sometimes serious drug-induced liver injury.
Current evidence suggests clinically apparent liver injury is uncommon, but the precise incidence is unknown.
Case reports cannot provide a reliable population-wide percentage because they lack a denominator.
Published cases have often developed during the first several weeks.
A comprehensive review reported symptom latency ranging from approximately 2 to 49 days, with a median of about 21 days.
That range does not define a universal window.
Frequently reported signs and symptoms include:
These findings are not unique to kratom-associated liver injury.
Yes.
Jaundice has been one of the most prominent findings in published kratom-associated liver-injury cases.
All 11 patients in the DILIN case series ultimately developed jaundice.
It can in documented liver-injury cases.
Published cases have reported abnormalities involving ALT, AST, alkaline phosphatase, bilirubin, and other liver-related measurements.
No clear dose threshold has been established.
The 2026 systematic review found that amount, formulation, frequency, and duration were incompletely reported in most cases.
Current research has not established a specific gram amount guaranteed to prevent kratom-associated liver injury.
There is no scientifically validated rule saying daily exposure always causes liver injury or that less frequent exposure eliminates the risk.
Frequency and duration remain insufficiently characterized in the case literature.
Yes.
Preexisting liver disease was documented in only 3 of the 32 cases included in the 2026 systematic review.
Most published cases improved, but outcomes have varied.
The 2026 review identified four cases that progressed to liver transplantation.
Yes.
Mitragynine undergoes extensive metabolism, with CYP3A4 playing an important role.
A controlled human study has also demonstrated CYP3A4-mediated conversion of mitragynine into 7-hydroxymitragynine.
No.
Liver metabolism and liver toxicity are separate concepts.
Many substances are metabolized by the liver without causing clinically significant injury.
They may complicate some products, but current evidence does not establish contaminants as the explanation for all cases.
Some implicated products analyzed in the DILIN investigation contained expected kratom alkaloids without the additional adulterants or toxicants investigators tested for.
Current evidence is insufficient to quantify liver risk by product format.
The liver-injury literature frequently lacks detailed information about the exact kratom formulation involved.
No.
7-OH naturally occurs at low levels in kratom leaf, while some newer products contain added or enhanced concentrations.
They should not automatically be treated as chemically equivalent to traditional botanical kratom.
No.
Product testing can provide information about specified alkaloids and contaminants, but it cannot guarantee that an individual will not experience an adverse reaction.
No.
Jaundice is a sign that warrants medical evaluation regardless of the suspected cause.
Published kratom-associated liver-injury cases demonstrate that significant liver dysfunction can occur.
Kratom has been linked to documented cases of acute liver injury.
The strongest current evidence does not support the claim that kratom inevitably damages the liver.
It also does not support the claim that people with healthy livers have nothing to worry about.
What research currently shows is:
The most accurate answer is therefore:
Kratom-associated liver injury appears uncommon, but it is a documented and potentially serious adverse event. Current evidence does not allow researchers to reliably predict who will develop it, determine a universal toxic amount, or guarantee that a particular product or exposure pattern eliminates the risk.